Johns Hopkins biomedical engineers have teamed up with clinicians to create a new drug-delivery strategy for a type of central vision loss caused by blood vessel growth at the back of the eye, where such growth should not occur.
A diagram of a healthy human eye. The macula is marked at the back of the eye with a black oval.
National Eye Institute, National Institutes of Health
In addition to testing a new drug that effectively stops such runaway vessel growth in mice, the team gave the drug a biodegradable coating to keep it in the eye longer. If proven effective in humans, the engineers say, it could mean only two or three needle sticks to the eye per year instead of the monthly injections that are the current standard of care.
The new drug, in its time-release coating, was tested in mice with abnormalities similar to those experienced by people with neovascular age-related macular degeneration, or "wet" AMD. A description of the study results, currently available online, will be published in the October issue of the journal Biomaterials.
"If you lose central vision, you can't drive a car and you can't see your grandchildren," says Jordan Green, Ph.D., assistant professor of biomedical engineering and ophthalmology at The Johns Hopkins University. "You're willing to do what it takes to keep your sight. We hope that our system will work in people, and make invasive treatments much less frequent, and therefore easier to comply with, and safer."
According to Peter Campochiaro, M.D., the George S. & Dolores Doré Eccles Professor of Ophthalmology & Neuroscience, approximately 200,000 Americans suffer from central vision loss caused by wet AMD. The macula is a few square centimeters of tissue in the center of the retina at the back of the eye. It is responsible for the majority of a person's high-resolution vision, especially the high-res vision needed for driving and reading. There are normally no blood vessels in the outer part of the retina because it needs to be unobstructed to capture complete images. In patients with wet AMD, blood vessels from behind the retina can break through into the macula and leak fluid that reduces vision. This initially causes reversible loss of vision, but, if left untreated, visual loss becomes permanent.
Currently, wet AMD patients are treated with frequent (as often as once a month) injections into the eye of a drug that blocks one of the major stimulators of abnormal blood vessel growth. "Patients are given localized antibacterial and pain-numbing agents, and then a very fine needle is passed through the white of the eye into the central cavity where the drug is injected. It's not painful, but it isn’t something that patients enjoy," says Campochiaro. “The frequent visits for injections are a burden and each injection carries a small risk of infection, so one of our goals is to find new approaches that allow for fewer visits and injections.”
Green's laboratory, which specializes in designing new drug-delivery systems, worked with Campochiaro and Aleksander Popel, Ph.D., professor of biomedical engineering, whose laboratory discovered the new drug — a short piece of protein that blocks the growth of unwanted blood vessels. (The drugs currently on the market for treating wet AMD are longer protein pieces or full-length proteins that could become inactive if given a biodegradable coating.)
When the team tested the drug on cells grown in the lab, they found that it killed blood vessel cells and prevented growth of new blood vessels. The same effect was found when the drug was injected into the eyes of mice with abnormal blood vessels like those seen in wet AMD, but, as with the current standard treatment, the drug was only effective for about four weeks since the watery contents inside the eye gradually flushed it out.
The team’s solution, says Green, was to slow the release and depletion of the drug by covering it in non-toxic, biodegradable coatings. They first created "nanoparticles," tiny little spheres filled with the drug. When the spheres were placed in a watery environment, the water gradually broke down the coating and released the drug a little at a time. To maximize this effect, the team created larger spheres, called microparticles, filled with about a hundred nanoparticles per microparticle, and held together by another type of biodegradable "glue." The end result is something like a scoop of gumball ice cream. As the ice cream gets licked away, more and more gumballs (nanoparticles) are exposed.
Testing their microparticles in mice, the team found that the drug persisted in their eyes for at least 14 weeks, more than three times as long as the current treatment. Green says that the treatments may last longer in humans than in mice, but clinical trials will not begin before further testing in other animals.
Other authors of the report include Ron Shmueli, Masayuki Ohnaka, Akiko Miki, Niranjan Pandey, Raquel Lima e Silva, Jacob Koskimaki and Jayoung Kim, all of the Johns Hopkins University School of Medicine.
This work was supported by grants from the National Eye Institute (1R1EY022986, R01EY012609), the Wallace H. Coulter Foundation and the Edward N. & Della L. Thome Memorial Foundation.Media Contacts:
Catherine Kolf | EurekAlert!
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
17.01.2017 | Earth Sciences
17.01.2017 | Materials Sciences
17.01.2017 | Architecture and Construction